论文部分内容阅读
现今,恶性淋巴瘤可分为何杰金氏病与非何杰金淋巴瘤两大类。何杰金氏病至近些年来还有许多问题不清楚,与20年前相比治疗效果虽有进步,但对其本质还有许多问题未得到解决。相反非何杰金淋巴瘤却有了很大变化,这与近20年来淋巴细胞免疫学迅速发展有关。过去对非何杰金淋巴瘤的诊断不得不依靠病理学家,而现在临床医生能在较大程度上作出诊断,并且在阐明其病态方面,也能从临床方面得到启示。本稿主要阐述恶性淋巴瘤中的非何杰金淋巴瘤的变化,并从临床上略加探讨存在的问题。近20年间见到了属于恶性淋巴瘤的2、3种新的疾病。如Burkitts淋巴瘤,免疫母细胞淋巴结病(immunoblastic lymph-oadenopathy,IBL),皮肤T细胞淋巴瘤(cutaneousT-cell lymphoma,CTL)等。这些也属于非何杰金淋巴瘤。一对非何杰金淋巴瘤认识的变迁
Today, malignant lymphoma can be divided into Hodgkin’s disease and non-Hodgkin’s lymphoma two categories. Hodgkin’s disease to many problems in recent years is not clear, compared with 20 years ago, although the treatment effect of progress, but its essence, there are many problems have not been solved. On the contrary, non-Hodgkin lymphoma has undergone great changes, which is related to the rapid development of lymphocyte immunology in the past 20 years. In the past, diagnosis of non-Hodgkin’s lymphoma has had to rely on pathologists, and now clinicians are able to make a diagnosis to a large extent and from the clinical point of view to elucidate their pathology. This manuscript mainly describes the changes of non-Hodgkin’s lymphoma in malignant lymphoma and briefly discusses the existing problems from the clinic. Nearly 20 years have seen 2,3 kinds of new diseases belonging to malignant lymphoma. Such as Burkitts lymphoma, immunoblastic lymph-oadenopathy (IBL), cutaneous T-cell lymphoma (CTL) and the like. These also belong to non-Hodgkin’s lymphoma. A change in understanding of non-Hodgkin’s lymphoma